Publication Name	World Journal of Gastroenterology
Manuscript ID	86619
Country	Canada

Received	2023-06-28 05:27
Peer-Review Started	2023-06-28 05:29
To Make the First Decision
Return for Revision	2023-08-15 21:54
Revised	2023-08-23 01:33
Second Decision	2023-09-12 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-09-12 17:14
Articles in Press	2023-09-12 17:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-09-19 01:54
Publish the Manuscript Online	2023-09-25 09:07

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Meta-Analysis
Article Title	Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
Manuscript Source	Unsolicited Manuscript
All Author List	Kai Zhu, Rohan Kakkar, Daljeet Chahal, Eric M Yoshida and Trana Hussaini
Funding Agency and Grant Number
Corresponding Author	Trana Hussaini, BPharm, MHSc, PharmD, Associate Professor, Pharmacist, BC Liver Transplant Program, Vancouver General Hospital, 899 West 12th Avenue, Vancouver V5Z 1M9, BC, Canada. trana.hussaini@vch.ca
Key Words	Non-alcoholic fatty liver disease; Fatty liver; Metabolic-associated fatty liver; Semaglutide
Core Tip	Semaglutide demonstrates significant histologic improvements, with a higher likelihood of non-alcoholic steatohepatitis resolution and improved steatosis, lobular inflammation, and hepatocellular ballooning, but it does not significantly improve fibrosis stage compared to placebo. Furthermore, semaglutide results in radiologic improvements in liver stiffness and steatosis, liver enzymes, as well as cardiometabolic effects on body weight and HgA1c, while maintaining a well-tolerated safety profile.
Publish Date	2023-09-25 09:07
Citation	Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338
URL	https://www.wjgnet.com/1007-9327/full/v29/i37/5327.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i37.5327

Full Article (PDF)	WJG-29-5327-with-cover.pdf
Full Article (Word)	WJG-29-5327.docx
PRISMA 2009 Checklist	86619-PRISMA 2009 checklist.pdf
Manuscript File	86619_Auto_Edited-LM.docx
Answering Reviewers	86619-Answering reviewers.pdf
Audio Core Tip	86619-Audio core tip.mp3
Biostatistics Review Certificate	86619-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	86619-Conflict-of-interest statement.pdf
Copyright License Agreement	86619-Copyright license agreement.pdf
Supplementary Material	86619-Supplementary material.pdf
Peer-review Report	86619-Peer-review(s).pdf
Scientific Misconduct Check	86619-Bing-Chen YL-2.png
Scientific Editor Work List	86619-Scientific editor work list.pdf
CrossCheck Report	86619-CrossCheck report.pdf